aTYR Pharma director granted 50,000 stock options

aTYR PHARMA INC director Svetlana Lucas received a grant of stock options covering 50,000 shares of common stock.

Rhea-AI Filing Summary

aTYR PHARMA INC director Svetlana Lucas received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $0.95 per share and expire on May 11, 2036.

The grant was made under the company’s non-employee director compensation policy. The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving on the board. This is a compensation-related award rather than an open-market transaction.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Lucas Svetlana

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 50,000 contracts (Direct)

Footnotes (1)

1. F1. The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

Key Figures

Options granted: 50,000 options Exercise price: $0.95 per share Shares underlying options: 50,000 shares +3 more

6 metrics

Options granted 50,000 options Stock Option (right to buy) grant to director

Exercise price $0.95 per share Exercise price of stock option grant

Shares underlying options 50,000 shares Common stock underlying granted options

Expiration date May 11, 2036 Option term end date

Post-grant derivative holdings 50,000 options Total derivative securities following transaction

Vesting date trigger May 11, 2027 Latest vesting date if earlier meeting does not occur

Key Terms

Stock Option (right to buy), non-employee director compensation policy, vests in full, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

non-employee director compensation policy financial

"The option, granted pursuant to the Issuer's non-employee director compensation policy"

vests in full financial

"The option ... vests in full on the earlier of (i) May 11, 2027"

Annual Meeting of Stockholders financial

"or (ii) the Issuer's 2027 Annual Meeting of Stockholders"

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did aTYR PHARMA (ATYR) report for Svetlana Lucas?

aTYR PHARMA reported a grant of stock options to director Svetlana Lucas covering 50,000 shares of common stock. These options are part of the non-employee director compensation policy and provide potential future ownership if she chooses to exercise them.

What is the exercise price of the new aTYR PHARMA (ATYR) stock options?

The granted stock options have an exercise price of $0.95 per share. This is the fixed price at which Svetlana Lucas may purchase aTYR PHARMA common stock if she exercises the options after they vest and before they expire in May 2036.

When do Svetlana Lucas’s aTYR PHARMA (ATYR) stock options vest?

The options vest in full on the earlier of May 11, 2027, or aTYR PHARMA’s 2027 Annual Meeting of Stockholders. Vesting is conditioned on her continued service on the board of directors through that vesting date or meeting date, whichever comes first.

When do the aTYR PHARMA (ATYR) stock options granted to Svetlana Lucas expire?

The stock options expire on May 11, 2036. After this expiration date, the options can no longer be exercised. This long-dated term gives the director a multi-year window to decide whether to exercise based on her circumstances.

Is the aTYR PHARMA (ATYR) Form 4 transaction an open-market purchase or sale?

The reported transaction is a grant or award of stock options, not an open-market purchase or sale. It reflects compensation for board service, with 50,000 options awarded at a $0.95 exercise price and subject to future vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lucas Svetlana

(Last) (First) (Middle)

C/O ATYR PHARMA, INC.

10240 SORRENTO VALLEY ROAD, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.95	05/11/2026		A		50,000		(1)	05/11/2036	Common Stock	50,000	$0.00	50,000	D

Explanation of Responses:

1. The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

	/s/ Nancy E. Denyes, as Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)